Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Myristic Acid Serum Levels and Their Significance for Diagnosis of Systemic Inflammatory Response, Sepsis, and Bacteraemia

R. Zazula, M. Moravec, F. Pehal, T. Nejtek, M. Protuš, M. Müller

. 2021 ; 11 (4) : . [pub] 20210416

Jazyk angličtina Země Švýcarsko

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc21017951

Grantová podpora
TUH, 00064190 Ministerstvo Zdravotnictví Ceské Republiky
IKEM, IN 00023001 Ministerstvo Zdravotnictví Ceské Republiky

Myristic acid is identified as a metabolite with the highest diagnostic sensitivity and specificity in the metabolome of patients with bacteraemia. Its significant decrease has been observed in patients with septic shock not responding to treatment. Another study has reported a close correlation of myristic acid levels with the outcome of severe trauma patients. Myristic acid concentrations were investigated in a cohort of septic patients and patients with Systemic Inflammatory Response Syndrome (SIRS) in 5 consecutive days following diagnosis and compared to healthy controls. The study population groups-Sepsis 34, SIRS 31, and Healthy Control 120 patients were included. Serum samples were analyzed using gas chromatography and mass spectrometry. The myristic acid levels in the Sepsis Group and SIRS Group were found to be significantly higher when compared to healthy controls. The serum concentration of myristic acid in septic patients with bacteraemia was higher than in septic patients without bacteraemia. Most patients with sepsis and SIRS had the highest levels of myristic acid within 24 h after an established diagnosis. Myristic acid should be considered as a new candidate marker of severe inflammation and sepsis. A simplified analysis and sufficient body of validated data are necessary steps towards the introduction of this metabolite into routine clinical practice.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc21017951
003      
CZ-PrNML
005      
20210729104100.0
007      
ta
008      
210726s2021 sz f 000 0|eng||
009      
AR
024    7_
$a 10.3390/jpm11040306 $2 doi
035    __
$a (PubMed)33923419
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a sz
100    1_
$a Zazula, Roman $u Department of Anesthesiology and Intensive Care, First Faculty of Medicine, Charles University and Thomayer University Hospital, 140 59 Prague, Czech Republic
245    10
$a Myristic Acid Serum Levels and Their Significance for Diagnosis of Systemic Inflammatory Response, Sepsis, and Bacteraemia / $c R. Zazula, M. Moravec, F. Pehal, T. Nejtek, M. Protuš, M. Müller
520    9_
$a Myristic acid is identified as a metabolite with the highest diagnostic sensitivity and specificity in the metabolome of patients with bacteraemia. Its significant decrease has been observed in patients with septic shock not responding to treatment. Another study has reported a close correlation of myristic acid levels with the outcome of severe trauma patients. Myristic acid concentrations were investigated in a cohort of septic patients and patients with Systemic Inflammatory Response Syndrome (SIRS) in 5 consecutive days following diagnosis and compared to healthy controls. The study population groups-Sepsis 34, SIRS 31, and Healthy Control 120 patients were included. Serum samples were analyzed using gas chromatography and mass spectrometry. The myristic acid levels in the Sepsis Group and SIRS Group were found to be significantly higher when compared to healthy controls. The serum concentration of myristic acid in septic patients with bacteraemia was higher than in septic patients without bacteraemia. Most patients with sepsis and SIRS had the highest levels of myristic acid within 24 h after an established diagnosis. Myristic acid should be considered as a new candidate marker of severe inflammation and sepsis. A simplified analysis and sufficient body of validated data are necessary steps towards the introduction of this metabolite into routine clinical practice.
655    _2
$a časopisecké články $7 D016428
700    1_
$a Moravec, Michal $u Department of Anesthesiology and Intensive Care, First Faculty of Medicine, Charles University and Thomayer University Hospital, 140 59 Prague, Czech Republic
700    1_
$a Pehal, František $u Department of Anesthesiology and Intensive Care, First Faculty of Medicine, Charles University and Thomayer University Hospital, 140 59 Prague, Czech Republic
700    1_
$a Nejtek, Tomáš $u Department of Anesthesiology and Intensive Care, First Faculty of Medicine, Charles University and Thomayer University Hospital, 140 59 Prague, Czech Republic
700    1_
$a Protuš, Marek $u Department of Anaesthesiology, Resuscitation and Intensive Care, Institute for Clinical and Experimental Medicine, First Faculty of Medicine, Charles University, 140 21 Prague, Czech Republic
700    1_
$a Müller, Martin $u Department of Anesthesiology and Intensive Care, First Faculty of Medicine, Charles University and Thomayer University Hospital, 140 59 Prague, Czech Republic
773    0_
$w MED00203320 $t Journal of personalized medicine $x 2075-4426 $g Roč. 11, č. 4 (2021)
856    41
$u https://pubmed.ncbi.nlm.nih.gov/33923419 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20210726 $b ABA008
991    __
$a 20210729104059 $b ABA008
999    __
$a ind $b bmc $g 1676479 $s 1138393
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2021 $b 11 $c 4 $e 20210416 $i 2075-4426 $m Journal of personalized medicine $n J. pers. med. $x MED00203320
GRA    __
$a TUH, 00064190 $p Ministerstvo Zdravotnictví Ceské Republiky
GRA    __
$a IKEM, IN 00023001 $p Ministerstvo Zdravotnictví Ceské Republiky
LZP    __
$a Pubmed-20210726

Najít záznam

Citační ukazatele

Nahrávání dat ...

Možnosti archivace

Nahrávání dat ...